The historical rank and industry rank for Pharming Group's Pretax Margin % or its related term are showing as below:
PHAR'
s Pretax Margin % Range Over the Past 10 Years
Min: -110.48 Med: 2.03 Max: 27.62
Current: 5.36
PHAR's Pretax Margin % is ranked better than 76.11% of 946
companies
in the Biotechnology industry
Industry Median: -90.5
vs PHAR: 5.36
Pharming Group (NAS:PHAR) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Pharming Group Pretax Margin % Related Terms
Pharming Group Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Pharming Group's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHAR vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Pharming Group's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharming Group Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharming Group's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Pharming Group's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharming Group (PHAR) has a Pretax Margin % of -6.56% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Pharming Group and its competitors. According to the industry distribution chart, Pharming Group ranks #226 out of 946 companies in the Biotechnology industry, placing it in the top 23.9%.
Is Pharming Group's Pretax Margin % too high?
Pharming Group's current Pretax Margin % is -6.56%. Based on the distribution chart, Pharming Group ranks #226 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharming Group has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #226 out of 946 companies for Pretax Margin %. This places Pharming Group in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Pharming Group and its competitors. Pharming Group's current Pretax Margin % is -6.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.42, compared to a current price of $13.34 — trading 7.5% below its estimated fair value. The current Pretax Margin % is -6.56%. Pharming Group's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Pharming Group (PHAR), the current Pretax Margin % is -6.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharming Group (PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued.
The current stock price of $13.34 is trading 7.5% below its estimated GF Value™ of $14.42.
GuruFocus considers Pharming Group to be Fairly Valued.
Key valuation signals for PHAR:
Pretax Margin %: -6.56%
GF Value™: $14.42 vs. price of $13.34 (7.5% below fair value)
No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
79GF Score
Get the complete analysis for PHAR
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHAR has been successfully added to your 
